Subscribe to RSS
DOI: 10.1055/s-0028-1128144
© Georg Thieme Verlag KG Stuttgart · New York
Early Insulin Treatment to Prevent Cardiovascular Disease in Prediabetes and Overt Diabetes
Publication History
received 06.09.2008
accepted 20.12.2008
Publication Date:
12 February 2009 (online)

Abstract
Type 2 diabetes mellitus (DM) is a major risk factor for cardiovascular disease (CVD), and CVD represents the leading cause of death in people with type 2 DM. The cardiovascular risk is increased long before diabetes is diagnosed, in the prediabetes stage, when impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) develop. These stages are characterized by dysglycemia, defined as any elevated fasting or postprandial glycemia, extending from the normal range into diabetic range, associated with an increased risk of CVD. Due to metabolic memory demonstrated for type 2 DM as well, early interventions addressed to achieve and maintain glycemic control are required for long-term benefits in terms of both microvascular and macrovascular complications. The recommendation of early insulin therapy in type 2 DM is sustained by its pleiotropic effects, which may be cardioprotective and potentially anti-atherosclerotic. Insulin therapy in prediabetes and earlier in type 2 DM, could be a strategy in preventing cardiovascular disease and type 2 DM progression. To test this hypothesis, a large trial has been designed. Outcome Reduction with an Initial Glargine Intervention trial (ORIGIN) is an international, multicenter, randomized controlled, 2 × 2 factorial trial, investigating the possibility to prevent cardiovascular morbidity and mortality in people with type 2 DM, IGT, and/or IFG, and high cardiovascular risk by treating the normoglycemia with either insulin glargine or omega-3 fatty acid, compared to the standard intervention.
Key words
prediabetes - insulin - dysglycemia - cardiovascular disease
References
- 1
International Diabetes Federation
.
Diabetes Atlas, third edition, 2007.
, Available from
http://www.eatlas.idf.org
, Accessed on 23 August 2008
MissingFormLabel
- 2
International Diabetes Federation
.
Diabetes and Cardiovascular Disease: Time to Act 2001.
, Available from
http://http//:www.idf.org
, Accessed on 23 August 2008
MissingFormLabel
- 3
Fox CS, Coady S, Sorlie PD, D’Agostino
Sr
RB, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ.
Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham
Heart Study.
Circulation.
2007;
115
1544-1550
MissingFormLabel
- 4
American Diabetes Association, National Heart, Lung, and Blood Institute, Juvenile
Diabetes Foundation International, National Institute of Diabetes and Digestive and
Kidney Diseases, American Heart Association
.
Diabetes mellitus: a major risk factor for cardiovascular disease: a joint editorial
statement by the American Diabetes Association; the National Heart, Lung, and Blood
Institute; the Juvenile Diabetes Foundation International; the National Institute
of Diabetes and Digestive and Kidney Diseases; and the American Heart Association.
Circulation.
1999;
100
1132-1133
MissingFormLabel
- 5
Gerich JE.
Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
Clin Cornerstone.
2007;
8
53-68
MissingFormLabel
- 6
Expert Panel on Detection, Evaluation.
Treatment of High Blood Cholesterol in Adults
.
Executive summary of the Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
MissingFormLabel
- 7
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ.
Primary prevention of cardiovascular diseases in people with diabetes mellitus: A
scientific statement from the American Heart Association and the Amercian Diabetes
Association.
Diabetes Care.
2007;
30
162-172
MissingFormLabel
- 8
Ho JE, Paultre F, Mosca L.
Diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women?
Data from the women's pooling project.
Stroke.
2003;
34
2812-2816
MissingFormLabel
- 9
Jeerakathil T, Johnson JA, Simpson SH, Majumdar SR.
Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes
compared with persons without diabetes. A population-based cohort study.
Stroke.
2007;
38
1739-1743
MissingFormLabel
- 10
Yusuf S, Hawken S, Ounpuu S.
on behalf of the INTERHEART Study Investigators
.
Effect of potentially modifiable risk factors associated with myocardial infarction
in 52 countries (the INTERHEART study): case-control study.
Lancet.
2004;
364
937-952
MissingFormLabel
- 11
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction.
N Engl J Med.
1998;
339
229-234
MissingFormLabel
- 12
Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, Kuulasmaa K, Palomäki P, Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H, Torppa J, Tuomilehto J, Kesäniemi YA, Pyörälä K, Salomaa V.
Myocardial infarction in diabetic and non-diabetic persons with and without prior
myocardial infarction: the FINAMI Study.
Diabetologia.
2005;
48
2519-2524
MissingFormLabel
- 13
Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C.
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior
myocardial infarction carry the same cardiovascular risk. A population study of 3.3
million people.
Circulation.
2008;
117
1945-1954
MissingFormLabel
- 14
American Diabetes Association
.
Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care.
2008;
31
S55-S60
MissingFormLabel
- 15
IDF/WHO
.
Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia.
2006;
MissingFormLabel
- 16
Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK.
Cardiovascular risk factors in confirmed prediabetic individuals.
Does the clock for coronary heart disease start ticking before the onset of clinical
diabetes? JAMA.
1990;
263
2893-2898
MissingFormLabel
- 17
Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE.
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.
Diabetes Care.
2002;
25
1129-1134
MissingFormLabel
- 18
Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N.
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European
prospective investigation of cancer and nutrition (EPIC-Norfolk).
BMJ.
2001;
322
15-18
MissingFormLabel
- 19
Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N.
Association of hemoglobin A1c with cardiovascular disease and mortality in adults:
The European prospective investigation into cancer in Norfolk.
Ann Intern Med.
2004;
141
413-420
MissingFormLabel
- 20
Gerstein HC.
Glucose: a continuous risk factor for cardiovascular disease.
Diabetic Med.
1997;
14
S25-S31
MissingFormLabel
- 21
Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw KT, Wareham NJ, Griffin SJ.
Evaluation of the Framingham risk score in the European Prospective Investigation
of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of
coronary heart disease events?.
Arch Intern Med.
2008;
168
1209-1216
MissingFormLabel
- 22
Gerstein HC, Yusuf S.
Dysglycaemia and risk of cardiovascular disease.
Lancet.
1996;
347
949-950
MissingFormLabel
- 23
Gerstein HC, Capes SE.
Dysglycemia: A Key Cardiovascular Risk Factor.
Seminars in Vascular Medicine.
2002;
2
165-174
MissingFormLabel
- 24
Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E.
Fasting blood glucose: an underestimated risk factor for cardiovascular death.
Diabetes Care.
1999;
22
45-49
MissingFormLabel
- 25
Coutinho M, Gerstein HC, Wang Y, Yusuf S.
The relationship between glucose and incident cardiovascular events. A meta regression
analysis of published data from 20 studies of 95,783 individuals followed for 12.4
years.
Diabetes Care.
1999;
22
233-240
MissingFormLabel
- 26
Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, Khaw KT.
Glycated hemoglobin and risk of stroke in people without known diabetes in the European
Prospective Investigation Into Cancer (EPIC)–Norfolk Prospective Population Study:
A Threshold Relationship?.
Stroke.
2007;
38
271-275
MissingFormLabel
- 27
Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW.
Glycemic control and coronary heart disease risk in persons with and without diabetes:
The Atherosclerosis Risk in Communities Study.
Arch Intern Med.
2005;
165
1910-1916
MissingFormLabel
- 28
Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett A.
Glycaemia (haemoglobin A) and incident ischaemic stroke: the Atherosclerosis Risk
in Communities (ARIC) Study.
Lancet Neurol.
2005;
12
821-826
MissingFormLabel
- 29
Nichols GA, Hillier TA, Brown JB.
Normal fasting plasma glucose and risk of type 2 diabetes diagnosis.
Am J Med.
2008;
121
519-524
MissingFormLabel
- 30
Nathan DM, Davidson MB, Defronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B.
Impaired Fasting Glucose and Impaired Glucose Tolerance. Implications for care.
Diabetes Care.
2007;
30
753-759
MissingFormLabel
- 31
Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K.
Determinants of progression from impaired fasting glucose and impaired glucose tolerance
to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study,
Denmark.
Diabetologia.
2007;
50
293-297
MissingFormLabel
- 32
Asia Pacific Cohort Studies Collaboration
.
Blood glucose and risk of cardiovascular disease in the Asia Pacific region.
Diabetes Care.
2004;
27
2836-2842
MissingFormLabel
- 33
Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S.
GHb is a better predictor of cardiovascular disease than fasting or postchallenge
plasma glucose in women without diabetes:the Rancho Bernardo Study.
Diabetes Care.
1996;
19
450-456
MissingFormLabel
- 34
Barrett-Connor E, Ferrara A.
Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease
in older women and men: the Rancho Bernardo Study.
Diabetes Care.
1998;
21
1236-1239
MissingFormLabel
- 35
Wedick N, Wingard D, Barrett-Connor E.
A prospective study to identify the best glycemic predictors of nonfatal coronary
heart disease (CHD) and cardiovascular disease (CVD) mortality; the Rancho Bernardo
Study.
Am J Epidemiol.
2000;
151
((Suppl))
S38
MissingFormLabel
- 36
Kanaya AM, Christina L, Fyr W, Rekeneire N de, Shorr RI, Schwartz AV, Goodpaster BH, Newman AB, Harris T, Barrett-Connor E.
Predicting the development of diabetes in older adults: The derivation and validation
of a prediction rule.
Diabetes Care.
2005;
28
404-408
MissingFormLabel
- 37
Grundy SM, Brewer
Jr
HB, Cleeman JI, Smith
Jr
SC, Lenfant C.
for the Conference Participants.
.
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American
Heart Association Conference on Scientific Issues Related to Definition.
Circulation.
2004;
109
433-438
MissingFormLabel
- 38
International Diabetes Federation
.
The IDF consensus worldwide definition of the metabolic syndrome.
http://available at www.idf.org/idf_metasyndrome_definition.pdf
, Accessed 24 August 2008
MissingFormLabel
- 39
Després JP, Lemieux I.
Abdominal obesity and metabolic syndrome.
Nature.
2006;
444
881-887
MissingFormLabel
- 40
Despres JP, Poirier P, Bergeron J, Tremblay A, Lemieux I, Almeras N.
From individual risk factors and the metabolic syndrome to global cardiometabolic
risk.
Eur Heart J Suppl.
2008;
10
((Suppl B))
B24-B33
MissingFormLabel
- 41
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) Study Research Group
.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
N Engl J Med.
2005;
353
2643-2653
MissingFormLabel
- 42
Gaede P, Lund-Andersen H, Parving HH, Pedersen O.
Effect of a multifactorial intervention on mortality in type 2 diabetes.
N Engl J Med.
2008;
358
580-591
MissingFormLabel
- 43
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M.
Intensive insulin therapy prevents the progression of diabetic microvascular complications
in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective
6-year study.
Diabetes Res Clin Pract.
1995;
28
103-117
MissingFormLabel
- 44
UK Prospective Diabetes Study (UKPDS) Group
.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998;
352
837-853
MissingFormLabel
- 45
UK Prospective Diabetes Study (UKPDS) Group
.
Effect of intensive blood-glucose control with metformin on complications in overweight
patients with type 2 diabetes (UKPDS 34).
Lancet.
1998;
352
854-865
MissingFormLabel
- 46
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B.
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation
and adjustment of therapy a consensus statement from the American Diabetes Association
and the European Association for the Study of Diabetes.
Diabetes Care.
2006;
29
1963-1972
MissingFormLabel
- 47
IDF Clinical Guidelines Task Force
.
Global guideline for Type 2 diabetes. 2005.
, Available from
http://http//:www.idf.org
, Accessed on 30 August 2008
MissingFormLabel
- 48
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B.
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for
the initiation and adjustment of therapy. A consensus statement of the American Diabetes
Association and the European Association for the Study of Diabetes.
Diabetes Care.
2009;
32
1-11
MissingFormLabel
- 49
Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wendel H.
Effects of insulin treatment on cause specific one-year mortality and morbidity in
diabetic patients with acute myocardial infarctions.
Eur Heart J.
1996;
17
1337-1344
MissingFormLabel
- 50
Malmberg K.
Prospective randomized study of intensive insulin treatment of long-term survival
after acute myocardial infarction in patients with diabetes mellitus.
Br Med J.
1997;
314
1512-1515
MissingFormLabel
- 51
Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P.
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis
of randomized trials.
Am Heart J.
2006;
152
27-38
MissingFormLabel
- 52
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Goldenet SH.
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.
Ann Intern Med.
2004;
141
421-431
MissingFormLabel
- 53
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1-13
MissingFormLabel
- 54
The ADVANCE Collaborative Group
.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med.
2008;
358
2560-2572
MissingFormLabel
- 55
The Action to Control Cardiovascular Risk in Diabetes Study Group.
.
Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med.
2008;
358
2545-2559
MissingFormLabel
- 56 Duckworth WC. Cardiovascular outcomes by glycemic control treatment arm. ADA Meeting, San Francisco 2008
MissingFormLabel
- 57
UK Prospective Diabetes Study Group
.
UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes.
A progressive disease.
Diabetes.
1995;
44
1249-1258
MissingFormLabel
- 58
Tibaldi J.
Preserving insulin secretion in type 2 diabetes mellitus.
Expert Rev Endocrinol Metab.
2008;
3
147-159
MissingFormLabel
- 59
Kahn SE.
Clinical review 135: The importance of beta-cell failure in the development and progression
of type 2 diabetes.
J Clin Endocrinol Metab.
2001;
86
4047-4058
MissingFormLabel
- 60
Brown JB, Nichols GA, Perry A.
The burden of treatment failure in type 2 diabetes.
Diabetes Care.
2004;
27
1535-1540
MissingFormLabel
- 61
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B.
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation
and adjustment of therapy update regarding thiazolidinediones: a consensus statement
from the American Diabetes Association and the European Association for the Study
of Diabetes.
Diabetes Care.
2008;
31
173-175
MissingFormLabel
- 62
Westphal SA, Palumbo PJ.
A case for introducing insulin early in the treatment of type 2 diabetes mellitus.
Insulin.
2006;
1
65-69
MissingFormLabel
- 63
Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E.
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients
by transient intensive insulin treatment.
Diabetes Care.
1997;
20
1353-1356
MissingFormLabel
- 64
Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng JP.
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients
is associated with improvement of beta-cell function.
Diabetes Care.
2004;
27
2597-2602
MissingFormLabel
- 65
Noh YN, Lee SM, Kim EJ, Kim DY, Lee H, Lee JH, Ju-Han Lee, Park SY, Koo JH, Wang JH, Lim IJ, Choi SB.
Improvement of cardiovascular risk factors in patients with type 2 diabetes after
long-term continuous subcutaneous insulin infusion.
Diabetes/Metabolism Res Rev.
2008;
24
384-391
MissingFormLabel
- 66
Park S, Choi SB.
Induction of long-term normoglycemia without medication in Korean type 2 diabetes
patients after continuous subcutaneous insulin infusion therapy.
Diabetes Metab Res Rev.
2003;
19
124-130
MissingFormLabel
- 67
Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Lin J, Li M, Fu Z, Cheng H.
Effect of intensive insulin therapy on β-cell function and glycaemic control in patients
with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
Lancet.
2008;
371
1753-1760
MissingFormLabel
- 68
Nauck MA, Meier JJ, Creutzfeldt W.
Incretins and their analogues as new antidiabetic drugs.
Drug News Perspect.
2003;
16
413-422
MissingFormLabel
- 69
Tews D, Werner U, Eckel J.
Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic
beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and
insulin analogues.
Horm Metab Res.
2008;
40
172-180
MissingFormLabel
- 70
Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG.
Insulin treatment reverses the insulin resistance of type II diabetes mellitus.
Diabetes Care.
1982;
5
353-363
MissingFormLabel
- 71
Zhao L, Sun D, Cao F, Yin T, Wang H.
Can insulin resistance be reversed by insulin therapy?.
Med Hypoth.
2009;
72
34-35
MissingFormLabel
- 72
Vinik AI.
Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes
mellitus.
Insulin.
2006;
1
2-12
MissingFormLabel
- 73
Dandona P, Chaudhuri A, Ghanim H, Mohanty P.
Use of insulin to improve glycemic control in diabetes mellitus.
Cardiovascul Drugs Ther.
2008;
22
241-251
MissingFormLabel
- 74
Dandona P, Chaudhuri A, Ghanim H, Mohanty P.
Potential use of insulin as an anti-inflammatory drug.
Drug Develop Res.
2008;
69
101-110
MissingFormLabel
- 75
Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P.
Anti-inflammatory and profibrinolytic effect of insulin in acute st-segment–elevation
myocardial infarction.
Circulation.
2008;
109
849-854
MissingFormLabel
- 76
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T.
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people
with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled
trial.
Lancet.
2008;
371
1073-1084
MissingFormLabel
- 77
Mathieu C, Robberecht S.
Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type
2 diabetes patients.
Diabetes Obes Metab.
2008;
10
((Suppl 2))
14-23
MissingFormLabel
- 78
Yki-Jarvinen H, Dressler A, Ziemen M.
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin
glargine compared with bedtime NPH insulin during insulin combination therapy in type
2 diabetes. HOE 901/3002 Study Group.
Diabetes Care.
2000;
23
1130-1136
MissingFormLabel
- 79
Riddle MC.
The treat-to-target trial and related studies.
Endocr Pract.
2006;
12
((Suppl 1))
71-79
MissingFormLabel
- 80
Rosenstock J, Schwartz SL, Clark Jr CM, Park GD, Donley DW, Edwards MB.
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE
901) and NPH insulin.
Diabetes Care.
2001;
24
631-636
MissingFormLabel
- 81
Schreiber S.
Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years on.
Diabetes Obes Metab.
2008;
10
((Suppl 2))
24-34
MissingFormLabel
- 82
Janka HU.
Insulin therapy in elderly patients with type 2 diabetes.
Diabetes Obes Metab.
2008;
10
((Suppl 2))
35-41
MissingFormLabel
- 83
Dailey G.
Beyond insulin replacement: addressing the additional needs of the diabetes patient.
Diabetes Obes Metab.
2008;
10
((Suppl 2))
85-99
MissingFormLabel
- 84
Dailey G.
Optimum management of type 2 diabetes – timely introduction, optimization and intensification
of basal insulin.
Diabetes Obes Metab.
2008;
10
((Suppl 2))
5-13
MissingFormLabel
- 85
Davies M, Khunti K.
Insulin management in overweight or obese type 2 diabetes patients: the role of insulin
glargine.
Diabetes Obes Metab.
2008;
10
((Suppl 2))
42-49
MissingFormLabel
- 86
Davies M, Sinnassamy P, Storms F, Gomis R. on behalf of the AT.LANTUS Study Group .
Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes
sub-optimally controlled on premixed insulin therapies.
Diabetes Res Clin Pract.
2008;
79
368-375
MissingFormLabel
- 87
Hammer H, Klinge A.
Patients with type 2 diabetes inadequately controlled on premixed insulin: effect
of initiating insulin glargine plus oral antidiabetic agents on glycaemic control
in daily practice.
Int J Clin Pract.
2007;
61
2009-2018
MissingFormLabel
- 88
The ORIGIN Trial Investigators. .
Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J.
Rationale, design, and baseline characteristics for a large international trial of
cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome
Reduction with an Initial Glargine Intervention).
Am Heart J.
2008;
155
26.e1-26.e13
MissingFormLabel
- 89
Schwartz S.
Is there a rationale for insulin therapy in pre-diabetic individuals?.
Treat Endocrinol.
2006;
5
385-393
MissingFormLabel
- 90
Schacky C von.
A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased
blood triglyceride levels.
Vasc Health Risk Manag.
2006;
2
251-262
MissingFormLabel
- 91
Tsitouras PD, Gucciardo F, Salbe AD, Heward C, Harman SM.
High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but
does not affect other endocrine axes in healthy older adults.
Horm Metab Res.
2008;
40
199-205
MissingFormLabel
Correspondence
G. RomanMD
Clinical Center of Diabetes
Nutrition, Metabolic Diseases
2–4 Clinicilor Street
400006 Cluj-Napoca
Romania
Phone: +40/264/59 44 55
Fax: +40/264/59 95 78
Email: groman@umfcluj.ro